SCNI Scinai Immunotherapeutics Ltd.

Nasdaq biondvax.com


$ 1.18 $ 0.04 (3.51 %)    

Wednesday, 05-Nov-2025 12:25:01 EST
QQQ $ 625.29 $ 6.85 (1.11 %)
DIA $ 473.77 $ 2.90 (0.62 %)
SPY $ 680.35 $ 5.31 (0.79 %)
TLT $ 89.06 $ -0.45 (-0.5 %)
GLD $ 366.64 $ 0.19 (0.05 %)
$ 1.13
$ 1.14
$ 1.15 x 10
$ 1.19 x 2
$ 1.16 - $ 1.18
$ 1.13 - $ 6.18
108,237
na
5.25M
$ 1.50
$ 1.09
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2023 03-31-2023 10-Q
2 04-17-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 scinai-immunotherapeutic-awarded-grant-of-about-246k-from-israel-innovation-authority-to-finance-project-to-acquire-install-fill-and-finish-system-for-sterile-manufacturing

Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small-batch fill and finish ...

 scinai-imunotherapeutics-files-prospectus-relates-to-offer--sale-of-up-to-48m-american-depositary-shares

- SEC Filing

 scinai-to-discuss-monoclonal-antibody-pc111-for-rare-skin-diseases-in-upcoming-webinar

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I)...

 scinai-immunotherapeutics-signs-an-option-agreement-to-acquire-rare-disease-company-pincell-and-its-novel-antibody-for-treating-severe-dermatological-conditions-no-financial-terms-of-transaction-disclosed-files-an-application-for-12-million-grant-to-fund-next-stage-of-development

Scinai files an application for Euro 12 million grant to fund next stage of developmentPincell's monoclonal antibody, PC111...

 scinai-signs-10m-standby-equity-agreement-retains-control-over-stock-sales-to-yorkville

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused o...

 scinai-immunotherapeutics-announces-the-establishment-of-a-us-based-subsidiary-for-its-contract-development-and-manufacturing-services

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION